These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1515999)

  • 1. Antipyrine metabolism in patients with liver metastases from colorectal cancer.
    Grieco A; Barone C; Coletta P; Castellano R; Ragazzoni E; Cassano A; Astone A; Gambassi G
    Cancer; 1992 Sep; 70(6):1477-82. PubMed ID: 1515999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients.
    Grieco A; Castellano R; Matera A; Marcoccia S; Di Rocco P; Ragazzoni E; Vecchio FM; Gasbarrini G
    J Gastroenterol Hepatol; 1998 May; 13(5):460-6. PubMed ID: 9641640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of antipyrine in patients with extensive metastatic liver disease.
    Robertz-Vaupel GM; Lindecken KD; Edeki T; Funke C; Belwon S; Dengler HJ
    Eur J Clin Pharmacol; 1992; 42(5):465-9. PubMed ID: 1606991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver.
    Noda S; Kawata S; Miyoshi S; Minami Y; Tarui S
    Gastroenterol Jpn; 1989 Apr; 24(2):159-63. PubMed ID: 2545499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease.
    Krausz Y; Zylber-Katz E; Levy M
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):253-7. PubMed ID: 7450926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.
    Preiss R; Matthias M; Sohr R; Brockmann B; Hüller H
    J Cancer Res Clin Oncol; 1987; 113(6):593-8. PubMed ID: 2824523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients.
    Mahmoud M; Abdel-Kader R; Hassanein M; Saleh S; Botros S
    Eur J Pharmacol; 2007 Aug; 569(3):222-7. PubMed ID: 17628532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison between antipyrine and aminopyrine blood clearances.
    Kawasaki S; Imamura H; Kokudo N; Bandai Y; Sanjo K; Idezuki Y
    Hepatogastroenterology; 1992 Aug; 39(4):344-6. PubMed ID: 1427580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue zinc status and drug elimination in patients with chronic liver disease.
    Barry M; Keeling PW; Feely J
    Clin Sci (Lond); 1990 Jun; 78(6):547-9. PubMed ID: 2165886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
    Wensing G; Hoffmann K; Heidemann HT
    Z Gastroenterol; 1993 Jan; 31(1):15-9. PubMed ID: 8447150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between rifamycin-SV (R-SV) related hyperbilirubinaemia and antipyrine clearance as a new test of liver function in cirrhosis.
    Persico M; Romano M; Villano N; Montella F; Gentile S
    Eur J Clin Invest; 1994 Mar; 24(3):201-4. PubMed ID: 8033955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression.
    Coverdale SA; Samarasinghe DA; Lin R; Kench J; Byth K; Khan MH; Crewe E; Liddle C; George J; Farrell GC
    Am J Gastroenterol; 2003 Jun; 98(6):1384-90. PubMed ID: 12818285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of antipyrine clearance to measure liver damage in psoriatic patients receiving methotrexate.
    Paramsothy J; Strange R; Sharif H; Collins M; Shaw P; Lawrence CM
    Br J Dermatol; 1988 Dec; 119(6):761-5. PubMed ID: 3203069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipyrine kinetics in patients with primary biliary cirrhosis.
    von Moltke LL; Abernethy DR; Kaplan MM; Greenblatt DJ
    J Clin Pharmacol; 1993 Jan; 33(1):75-7. PubMed ID: 8429118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of antipyrine clearance in chronic liver diseases].
    Wang JL; Zhang F; Yuan SY
    Zhonghua Nei Ke Za Zhi; 1989 May; 28(5):295-7, 315-6. PubMed ID: 2553353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of flecainide in patients with cirrhosis of the liver.
    McQuinn RL; Pentikäinen PJ; Chang SF; Conard GJ
    Clin Pharmacol Ther; 1988 Nov; 44(5):566-72. PubMed ID: 3141098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of zinc supplementation on oxidative drug metabolism in patients with hepatic cirrhosis.
    Barry MG; Macmathuna P; Younger K; Keeling PW; Feely J
    Br J Clin Pharmacol; 1991 Apr; 31(4):488-91. PubMed ID: 2049261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon.
    Kitteringham NR; Büstgens L; Brundert E; Mineshita S; Ohnhaus EE
    Eur J Clin Pharmacol; 1984; 26(1):65-70. PubMed ID: 6714293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
    Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.